SS-31 (Elamipretide): A Research Overview

Introduction

SS-31, also designated elamipretide, MTP-131, and Bendavia, is a synthetic tetrapeptide belonging to the Szeto-Schiller (SS) peptide family. The compound is pharmacologically classified as a mitochondria-targeted inner-membrane peptide with selective affinity for cardiolipin, an anionic phospholipid concentrated at the inner mitochondrial membrane. SS-31 has attracted sustained scientific attention as a research tool for studying mitochondrial bioenergetics and has been evaluated in multiple clinical-trial programs sponsored by Stealth BioTherapeutics, culminating in FDA accelerated approval in 2025. Research-grade SS-31 from SpartaLabs is verified by independent third-party analytical testing for sequence fidelity and purity.

Background

Mitochondria are double-membrane organelles that house the electron transport chain (ETC), the principal site of ATP generation through oxidative phosphorylation. The inner mitochondrial membrane (IMM) is distinguished from all other cellular membranes by its unusually high content of cardiolipin — a bis-phosphatidyl glycerol lipid that accounts for approximately 20% of IMM phospholipid mass and is essential for the structural integrity of the cristae and for the supramolecular organization of ETC complexes [1].

Cardiolipin plays a non-redundant structural and functional role in anchoring cytochrome c at the IMM surface, where it serves as an electron carrier between Complex III and Complex IV. Under conditions of oxidative stress, peroxidation of cardiolipin has been reported to shift cytochrome c from its electron-carrier role to a peroxidase that amplifies lipid oxidation and can initiate apoptotic signaling [2]. The capacity to target this specific biochemical interaction is the central motivation for research on SS-31.

Chemistry and Structure

SS-31 is a water-soluble synthetic tetrapeptide with the sequence D-Arg-2',6'-dimethyltyrosine(Dmt)-Lys-Phe-NH2. Its molecular formula yields a compact molecular mass of approximately 640 daltons, substantially smaller than most biologics and many conventional small-molecule drugs. The structural motif alternates basic amino acid residues (D-arginine and lysine, conferring a formal charge of +3 at physiological pH) with aromatic residues (dimethyltyrosine and phenylalanine). This alternating aromatic-cationic architecture was identified by Zhao, Schiller, Szeto, and colleagues in 2004 as the structural basis for mitochondrial membrane targeting and antioxidant activity [1].

The dimethyltyrosine (Dmt) substitution at position 2 confers enhanced aromatic electron density relative to unmodified tyrosine and is reported to be important for both free-radical scavenging and cardiolipin binding affinity. The C-terminal amide (NH2) contributes to membrane permeability. The use of a D-amino acid at the N-terminus (D-Arg) confers resistance to proteolytic cleavage, extending the molecule's biological half-life relative to an all-L-amino acid analog.

A distinctive property of SS peptides as a class is their reported ability to accumulate at the IMM in a manner independent of mitochondrial membrane potential and non-saturable — a behavior attributed to the electrostatic attraction between the molecule's positive charge and the anionic surface of cardiolipin-rich membranes [3].

Pharmacological Classification

SS-31 is classified within a pharmacological category sometimes termed "mitochondria-targeted inner-membrane therapeutics" or "aromatic-cationic mitochondrial peptides." It is distinct from earlier classes of mitochondria-targeted compounds, such as the triphenylphosphonium (TPP)-conjugated antioxidants (e.g., MitoQ), which rely on the large negative mitochondrial membrane potential (approximately −180 mV) to drive electrophoretic accumulation. SS-31 does not carry the lipophilic cationic moiety required for potential-driven uptake and instead targets the membrane surface through cardiolipin affinity. Research on related mitochondrial compounds such as MOTS-c, a mitochondria-derived peptide regulating metabolic homeostasis through AMPK signaling, complements the mechanistic picture of IMM-targeted pharmacology.

The compound's primary reported pharmacological interaction — selective, reversible binding to cardiolipin at the IMM — was characterized in detail by Birk, Chao, Bracken, Warren, and Szeto (2014) in the British Journal of Pharmacology [2]. That work identified SS-31's capacity to modulate the cytochrome c/cardiolipin complex as a mechanistic node through which the peptide is reported to influence electron transport chain efficiency and ATP synthesis.

Mitchell and colleagues (2020) further characterized the membrane-binding mechanism using biophysical methods, reporting that SS-31 partitions into the interfacial region of cardiolipin-containing bilayers and modulates surface electrostatics in a charge-density-dependent manner, providing a physical chemistry framework for the compound's selectivity [3].

Regulatory Status

Elamipretide (as FORZINITY) received accelerated approval from the United States Food and Drug Administration (FDA) in September 2025 for the improvement of muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kilograms. This represents the first FDA approval for a compound directly targeting the mitochondrial inner membrane and the first approved pharmacological agent for Barth syndrome. Continued approval for this indication is contingent on verification of clinical benefit in confirmatory trials.

Clinical development of elamipretide spanned multiple indication areas over more than a decade. Programs in heart failure with reduced ejection fraction and primary mitochondrial myopathy generated a substantial body of safety and pharmacodynamic evidence that informed the Barth syndrome program and contributed to the regulatory science of mitochondrial therapeutics; the MMPOWER-3 phase 3 trial in primary mitochondrial myopathy did not meet its co-primary endpoints at 24 weeks, while a pre-specified subgroup analysis reported numerical differences by genetic subtype that are informing ongoing research into patient selection [4].

Outside the approved Barth syndrome indication, SS-31 is available as a research-use-only material.

Discovery History

The SS peptide family emerged from a research program conducted jointly by Hazel H. Szeto at Weill Cornell Medical College and Peter W. Schiller at the Institut de Recherches Cliniques de Montréal, initially focused on designing opioid-receptor-selective peptides with improved pharmacokinetic properties. The serendipitous observation that certain members of this chemical class concentrated at mitochondrial membranes and exhibited antioxidant properties redirected the research program toward mitochondrial pharmacology. Szeto and Birk described this discovery trajectory in a 2014 review published in Clinical Pharmacology & Therapeutics [5].

The foundational characterization of SS peptide antioxidants targeted to the inner mitochondrial membrane — including early evidence of the structural requirements for mitochondrial targeting and protection against oxidative cell death in vitro — was reported by Zhao, Zhao, Wu, Soong, Birk, Schiller, and Szeto in 2004 in the Journal of Biological Chemistry [1]. Subsequent work progressively defined cardiolipin as the specific molecular anchor, culminating in the preclinical and clinical development programs conducted under the auspices of Stealth BioTherapeutics, the company founded to advance elamipretide toward regulatory approval.

References

1. Zhao K, Zhao G-M, Wu D, Soong Y, Birk AV, Schiller PW, Szeto HH. Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. J Biol Chem. 2004;279(33):34682-34690. PMID: 15178689. DOI: 10.1074/jbc.M402999200

2. Birk AV, Chao WM, Bracken C, Warren JD, Szeto HH. Targeting mitochondrial cardiolipin and the cytochrome c/cardiolipin complex to promote electron transport and optimize mitochondrial ATP synthesis. Br J Pharmacol. 2014;171(8):2017-2028. PMID: 24134698. DOI: 10.1111/bph.12468

3. Mitchell W, Ng EA, Tamucci JD, Boyd KJ, Sathappa M, Coscia A, et al. The mitochondria-targeted peptide SS-31 binds lipid bilayers and modulates surface electrostatics as a key component of its mechanism of action. J Biol Chem. 2020;295(21):7452-7469. PMID: 32321821. PMC: PMC7247319. DOI: 10.1074/jbc.RA119.012094

4. Karaa A, Bertini E, Carelli V, Cohen BH, Enns GM, Falk MJ, et al. Efficacy and safety of elamipretide in individuals with primary mitochondrial myopathy: the MMPOWER-3 randomized clinical trial. Neurology. 2023;101(1):e42-e54. PMC: PMC10382259. DOI: 10.1212/WNL.0000000000207402

5. Szeto HH, Birk AV. Serendipity and the discovery of novel compounds that restore mitochondrial plasticity. Clin Pharmacol Ther. 2014;96(6):672-683. PMID: 25188726. PMC: PMC4267688. DOI: 10.1038/clpt.2014.174